by Raynovich Rod | Apr 4, 2022 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
Update-2 …4/6 In volatile end of day trading with Tech stocks and the NASDAQ hit hard down 2.2%, healthcare stocks were winners with the XLV up 1.5%. Other sector winners were staples, energy, real estate and utilities. As one pundit put it, ” the FED is...
by Raynovich Rod | Mar 28, 2022 | 2023-24 Life Science Portfolios, Biopharmaceuticals
4/1/22 Blah market but biotech and healthcare holds.Rally at last 30 min. Spec small caps on a green screen with both ARKG and XBI up. We are trading these stocks off a bottom. IWM up 0.9% to $207 level. Gene therapy stocks rallying: CRSP, EDIT, NTLA. Large caps...
by Raynovich Rod | May 18, 2021 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
May 20 The IBB was up over 2% and most biotechs were up. Momentum is expected to improve through July. We added to our bottom fishing on ARKG today at $78 level. Large caps perked up as well: BMY up 2.2%, AZN up 1,95%, RHHBY up 1.68%,LLY up 1.54%,...
by Raynovich Rod | Apr 12, 2021 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1 A Bit of a Rally despite the JNJ Vaccine Setback We have the best day for life science stocks in weeks despite a “pause” in distribution of the JNJ vaccine due to blood clots. Many experts don’t think it is a major problem just a...
by Raynovich Rod | Mar 22, 2021 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
Final Close 5/26: Dow up 1.39% at 33072, S&P 500 up 1.66% at 3974, , Nasdaq up 1.24% at13138 , Russell 2000 down 2.89%. IBB stable at close. Update-3 March 26. 3p EDT Another day of selling for biotech; I’ll look for trades over the weekend. IBB down 0.98 to...
by Raynovich Rod | Feb 28, 2021 | Biopharmaceuticals, Clinical Diagnostics and Tools
Best Rally Since June 2020 Eases Fear of Rate Rise A rise in Treasury yields curbed the Government Bond rout from last week. Vaccine roll out now with JNJ continues to be the driver with hopes of an improving economy.The Ten Year Treasury Yield dropped to 1.446% off...
by Raynovich Rod | Feb 22, 2021 | 2023-24 Life Science Portfolios, Biopharmaceuticals
Update-2 2/25…Correction seems more real just after market indices hit new highs yesterday: QQQ down 3.49% piercing 200 MA at $312.83. An unusual down day when both bonds and stocks take a hit over concerns about rapidly rising 10 yr TSY rates now yielding...
by Raynovich Rod | Nov 22, 2020 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-3 11/27 12p EST….Biotech rally underway with XBI at $130. Momentum market.IBB at 142.94.Small caps outpacing large caps. Vaccine stocks continue to run: BNTX, MRNA, NVAX. Gene editing movers : CRSP, EDIT, NTLA; mid caps strong. Large caps winners: AMGN...
by Raynovich Rod | Nov 18, 2020 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
Update-1 11/20…a bit of a sell-off at the end of the day probably on Mnuchin “war of words” with FED on $500B. “Re-opening type” trades in XLF and XLI both down 0.9%;XLK down 1%. Materials doing well CLF, FCX; chips mixed slightly down....
by Raynovich Rod | Oct 19, 2020 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
Update-3 10/21 11a EDT Another day with a brisk sell-off in momentum stocks. Coronavirus plays hit hard: BNTX, QDEL, NVAX, OSUR etc. Is this sentiment shift from lack of stimulus or just election anxiety? After the close: CRISPR Therapeutics (CRSP) down 12.95% to...